Reimbursement of anti-dementia drugs
The availability of medicines in general
Medicines in Latvia are included in one of four categories which determine the reimbursement rates:
- Medicines without which it is not possible to maintain life functions are reimbursed at 100%.
- Medicines without which there would be difficulties in ensuring a patient’s life functions are reimbursed at 90%.
- Medicines without which the current health status could not be maintained are reimbursed at 75%.
- Medicines which are necessary to improve a patient’s health condition are reimbursed at 50%. 
The availability of Alzheimer treatments
All four anti-dementia drugs are marketed in Latvia, but none of them are part of the reimbursement system.
 European Commission (2006): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland : Comparative tables
Last Updated: mercredi 15 juillet 2009